ICAM2

Across TCGA pan-cancer cohorts, ICAM2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ICAM2 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ICAM2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ICAM2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, CCRCC, and LUAD are the cancer types where ICAM2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.822	0.591	.002	49	view →
CCRCC	OS	Median	All	1.000	0.679	.013	9	view →
LUAD	DFS	Quartile	All	1.000	0.376	.008	7	view →
UCEC	DFS	Quartile	II,III,IV	0.343	0.853	.044	4	view →
PDAC	OS	Median	All	0.572	0.398	.044	3	view →
LSCC	DFS	Tertile	All	0.743	0.340	.034	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ICAM2–HNSC (OS)

Open the HNSC breakdown →